Overcoming Chemotherapy Resistance in Triple-Negative Breast Cancer with Nanocarrier-Delivered siRNA Therapeutics
Journal of Clinical Medicine · 18.03.2026 · 15 (6) · 2311
DOI: 10.3390/jcm15062311 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 18.03.2026. Verfasst von Andreea Crintea und 7 weiteren Autor:innen. Beteiligte Einrichtung: Medical Biochemistry, Department of Molecular Sciences, "Iuliu Haţieganu" University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) represents 10–20% of breast cancers and is characterized by the absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression, leaving cytotoxic chemotherapy as the main systemic treatment. However, rapid development of resistance, via drug efflux, enhanced DNA repair, apoptosis evasion, epithelial-to-mesenchymal transition, and tumor microenvironment protection, limit long-term efficacy. Small interfering RNA (siRNA) therapeutics can silence key resistance drivers, but their clinical potential is hindered by instability, poor biodistribution, and off-target effects. Nanocarrier-based delivery systems offer solutions by protecting siRNA, enhancing tumor accumulation, enabling targeted intracellular release, and permitting co-delivery with chemotherapeutics for synergistic effects. We conducted a narrative review in PubMed from database inception to August 2025. The included studies demonstrated that lipid, polymeric, inorganic, and hybrid nanocarriers can achieve efficient target knockdown, reverse drug resistance mechanisms, and significantly enhance antitumor responses in resistant TNBC models. Several platforms also reduced metastatic spread and improved survival in vivo. While preclinical results are compelling, clinical translation remains limited by incomplete safety profiling and heterogeneity in delivery efficiency. This review synthesizes mechanistic insights and delivery innovations, outlining a roadmap for translating siRNA-loaded nanocarriers into effective therapies for chemoresistant TNBC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medical Biochemistry, Department of Molecular Sciences, "Iuliu Haţieganu" University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania.
- Pharmacology, Toxicology and Clinical Pharmacology, Department of Morpho-Functional Sciences, "Iuliu Haţieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
- Histology Section, Department of Morpho-Functional Sciences, "Iuliu Haţieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
- Biology Section, University of Agricultural Sciences and Veterinary Medicine Cluj-Napoca, 400372 Cluj-Napoca, Romania.
- Faculty of Medical and Health Sciences, Babeș-Bolyai University, 400349 Cluj-Napoca, Romania.
- Institute of Oncology "Prof. Dr. Ion Chiricuță", 400015 Cluj-Napoca, Romania.
ORCID-Profile: Corina I Bocșan, Elena M Jianu, Camelia Munteanu, Alexandra M Crăciun, Ciprian N Silaghi
Zitieren
APA
Crintea, A., Bocșan, C. I., Jianu, E. M., Șovrea, A. S., Munteanu, C., Kubelac, M. P., Crăciun, A. M., & Silaghi, C. N. (2026). Overcoming Chemotherapy Resistance in Triple-Negative Breast Cancer with Nanocarrier-Delivered siRNA Therapeutics. Journal of Clinical Medicine, 15(6), 2311. https://doi.org/10.3390/jcm15062311
Vancouver
Crintea A, Bocșan CI, Jianu EM, Șovrea AS, Munteanu C, Kubelac MP, et al. Overcoming Chemotherapy Resistance in Triple-Negative Breast Cancer with Nanocarrier-Delivered siRNA Therapeutics. Journal of Clinical Medicine. 2026;15(6):2311. doi:10.3390/jcm15062311
BibTeX
@article{Crintea2026,
author = {Crintea, Andreea and Bocșan, Corina I and Jianu, Elena M and Șovrea, Alina S and Munteanu, Camelia and Kubelac, Milan P and Crăciun, Alexandra M and Silaghi, Ciprian N},
title = {Overcoming Chemotherapy Resistance in Triple-Negative Breast Cancer with Nanocarrier-Delivered siRNA Therapeutics},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {6},
pages = {2311},
doi = {10.3390/jcm15062311}
}
EUVIMED